San Diego, California, United States · Hybrid
Position Summary: We are seeking an experienced Senior Manager, Corporate Communications to lead and execute our external communications strategy. This role will be responsible for developing compelling corporate messagi…
Skills: Corporate Communications, External Communications Strategy, Investor Relations, Scientific Writing, Press Release Coordination
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
Lead the external communications strategy by developing corporate messaging and managing the company's digital presence. Coordinate press releases and maintain investor materials while collaborating with executive and scientific teams.
Requires a bachelor's degree in a scientific or communications field and at least 5 years of corporate communications experience in life sciences. Must be able to translate complex scientific data into engaging content and manage digital platforms.
Position Summary:
We are seeking an experienced Senior Manager, Corporate Communications to lead and execute our external communications strategy. This role will be responsible for developing compelling corporate messaging, supporting investor and business development activities, and managing the company's digital presence. The ideal candidate will bring prior experience in corporate communications, preferably within the biotechnology, pharmaceutical, or life sciences industry, and possess a strong scientific background with the ability to translate complex science into clear, engaging communications.
Key Responsibilities:
Qualifications:
Powering protein degradation for tomorrow's medicines
Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands. You can learn more information about Cullgen on our website: www.Cullgen.com
Offices: 12730 High Bluff Dr, Suite 250, San Diego, California 92130, US · 230 Chuan Hong Road, Building 6, Shanghai, 201202, CN
Powering protein degradation for tomorrow's medicines
Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands. You can learn more information about Cullgen on our website: www.Cullgen.com
Offices: 12730 High Bluff Dr, Suite 250, San Diego, California 92130, US · 230 Chuan Hong Road, Building 6, Shanghai, 201202, CN
